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Abstract
Amphotericin B has emerged as the therapy of choice for use against the leishmaniases.
Administration of the drug in its liposomal formulation as a single injection is being pro-
moted in a campaign to bring the leishmaniases under control. Understanding the risks
and mechanisms of resistance is therefore of great importance. Here we select amphoter-
icin B-resistant Leishmania mexicana parasites with relative ease. Metabolomic analysis
demonstrated that ergosterol, the sterol known to bind the drug, is prevalent in wild-type
cells, but diminished in the resistant line, where alternative sterols become prevalent.
This indicates that the resistance phenotype is related to loss of drug binding. Comparing
sequences of the parasites’ genomes revealed a plethora of single nucleotide polymor-
phisms that distinguish wild-type and resistant cells, but only one of these was found to
be homozygous and associated with a gene encoding an enzyme in the sterol biosyn-
thetic pathway, sterol 14α-demethylase (CYP51). The mutation, N176I, is found outside
of the enzyme’s active site, consistent with the fact that the resistant line continues to pro-
duce the enzyme’s product. Expression of wild-type sterol 14α-demethylase in the resis-
tant cells caused reversion to drug sensitivity and a restoration of ergosterol synthesis,
showing that the mutation is indeed responsible for resistance. The amphotericin B resis-
tant parasites become hypersensitive to pentamidine and also agents that induce oxida-
tive stress. This work reveals the power of combining polyomics approaches, to discover
the mechanism underlying drug resistance as well as offering novel insights into the
selection of resistance to amphotericin B itself.
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Author summary
Antimicrobial resistance threatens to reverse many of the great strides made against path-
ogens responsible for disease. Understanding the molecular processes underlying resis-
tance is crucial to quantifying and tackling the problem. Here we select resistance in
Leishmania parasites to amphotericin B, an antileishmanial drug of increasing impor-
tance. We then combine genome sequencing with untargeted and targeted metabolomics
analyses to identify a gene, sterol 14α-demethylase, mutation of which drives a change in
sterol metabolism and loss of ergosterol, the molecular target of amphotericin B. Accumu-
lation of a downstream intermediate of ergosterol biosynthesis indicated the enzyme itself
retains activity, but the pathway to ergosterol is truncated. Expression of wild-type sterol
14α-demethylase in the resistant cells restored amphotericin B sensitivity and normal
ergosterol production.
Introduction
The leishmaniases are a complex of diseases caused by parasitic protozoa of the genus Leish-
mania which are transmitted between people via the bite of an infected sandfly [1]. The specific
disease caused by the parasites depends upon which Leishmania species is responsible and
ranges from a self-limiting cutaneous form, through a mucocutaneous disease and a frequently
fatal visceral form [2]. Control is largely dependent upon the use of chemotherapy. In recent
years the polyene amphotericin B (AmB) has emerged as the treatment of choice where avail-
able, particularly in the liposomal formulation which abrogates some of the toxic effects associ-
ated with the parent compound itself [3]. The specificity of AmB relates to its mode of action
being mediated through a binding to the membrane sterol ergosterol, which is the primary ste-
rol of fungal and Leishmania membranes, while binding with less avidity to cholesterol [3], the
principal sterol of mammalian host membranes. It was suggested that AmB molecules poly-
merise at membranes where they bind, forming pores that cause membrane leakage to various
ions and this has been proposed as a key cause of death [4], although binding to ergosterol
alone is sufficient to cause death in fungi [5, 6].
AmB in a liposomal formulation, AmBisome, has emerged as a treatment of choice because
of the enhanced efficacy of the drug against macrophage-resident Leishmania parasites and the
accompanying reduction in host toxicity [7, 8]. Several trials using the drug as a combination
with other leishmanicides [9] indicate that AmB containing combinations offer promise for
future therapies [10]. Other trials [11] have indicated that a single injection of AmBisome is
efficacious, particularly in India where other drugs, including pentavalent antimony [12] and
miltefosine [13] are suffering from treatment failure and increasing resistance. The fact that
the incidence of resistance to AmB in fungi has been slow to emerge, in spite of over 50 years
of use [14], has underpinned a belief that the fitness costs associated with any resistance might
protect against the problem [15]. However, there are increasing reports of AmB resistance in
fungi [16–18]. Moreover, several reports of AmB treatment failure have been reported in leish-
maniasis patients in India [19, 20] and in immunocompromised patients in France [21] and
resistance to the drug has been reported to occur in at least one field isolate already [19]. Resis-
tance in that case was proposed to relate to several phenotypic changes to the parasite, notably
a change in sterol metabolism [19] and increase in defence against oxidative stress [22]. In
common with several reports in L. mexicana [23] and L. donovani [19, 24], selection of
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resistance was associated with the replacement of ergostane-type sterols with cholestane-type
sterols, the latter being less avid binders of AmB [3].
Other studies into changes occurring in selected AmB resistance in Leishmania point to alter-
ations in enzymes of cellular thiol [24, 25] and ascorbate [22] metabolism leading to an enhanced
resistance to oxidative stress being associated with selection. Although changes to C24-Δ-sterol
methyl transferase gene expression suggested a possible genetic marker for resistance [19, 26]
direct corroboration is lacking, and no specific gene mutations have yet been described that cor-
relate unequivocally with resistance. Understanding molecular mechanisms of drug resistance
provides potential biomarkers to assess the spread of resistance and can also offer routes to slow
the emergence of resistance or even bypass the problem. Due to the lack of economic incentivisa-
tion for new drug development, it is essential to retain existing drugs for neglected tropical dis-
eases, such as the leishmaniases, if we are to achieve aims of bringing the disease under control.
Here we use the complementary high throughput data approaches of metabolomics and
whole genome sequencing to reveal a gene whose mutation causes resistance to AmB in Leish-
mania mexicana.
Materials and methods
Cell culture and AmB resistance selection
Promastigotes of L. mexicana strain MNYC/BZ/62/M379 were cultured in Homem (GIBCO)
medium [27] supplemented with 10% foetal bovine serum—Gold (FBS) (PAA Laboratories
GmbH) starting at a density of 1 x 105 cells/ml and maintained at 27˚C, passaging once every
72 hours. The cells were selected for AmB resistance by increasing concentrations of the drug,
initially exposing cells to 0.0135 μM of AmB (Sigma-Aldrich) with stepwise doubling of the
drug concentration to a final concentration of 0.27 μM. Cells able to grow in the presence of
the drug were cloned under drug pressure by limiting dilution to 1 cell/ml in 20 ml of growth
medium and plated out into 96-well plates.
Drug sensitivity assays
Susceptibility of the cells to various drugs was determined using an adaptation of the Alamar
Blue assay [28]. A starting density of 1 × 106 cells/ml were incubated at 27˚C in the presence
of various drug concentrations for 72 hours in a 96-well microtiter plate. Resazurin (Sigma-
Aldrich) in 1× phosphate-buffered saline (PBS) (Sigma-Aldrich) pH 7.4 solution was added to a
concentration of 44.6 μM and cells incubated for a further 48 hours. The fluorescence of the
reacted dye was measured on a FLUOstar OPTIMA (BMG LabTech, Germany) spectrometer
set at excitation and emission wavelengths of 530 nm and 590 nm, respectively. The drugs used
in the susceptibility assays, unless stated otherwise, were bought from Sigma-Aldrich. To assess
the sensitivity to H2O2, wild-type and derived AmB resistant cells at a starting density of 2 × 106
cells/ml were exposed to 20 μM, 200 μM, 500 μM and 1 mM of H2O2 [29] in growth medium in
6-well plates. The response by the two cell lines to H2O2 were compared by observation under a
light microscope at different time points over 72 hours. An alternative test for H2O2 sensitivity
involved glucose oxidase as described previously [30]. Briefly, 180 μl of cells at 5 x 105cells/ml
were plated into a 96-well plate and 20 μl of glucose oxidase solution (Sigma-Aldrich) were
added in varying concentrations then tested using the AlamarBlue assay described above.
Cell body length determination
The cell body length of L. mexicana promastigotes was determined using the SoftWoRx 5.5
software on a DeltaVision Applied Precision Olympus IX71 microscope. Smears of cells from
Amphotericin B resistant Leishmania mexicana
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late log phase culture were spread onto a microscope slide. The cells were fixed in absolute
methanol overnight at -20˚C then rehydrated with 1 ml of 1 × PBS for 10 minutes. 50 μl of PBS
containing 1 μg/ml 4, 6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich) and 1% 1, 4-Dia-
zobicyclo-(2, 2, 2) octane (DABCO) (Sigma-Aldrich) were added to stain the cells. The cell
length was measured from the anterior end to the posterior end of the cell body.
Metabolite extraction and analysis by LC-MS untargeted metabolomics
Cells were grown to mid-log phase and 1 × 108 cells for each sample collected and metabolism
was quenched rapidly by cooling them to 4˚C in a dry ice/ethanol bath while mixing vigor-
ously to avoid freezing and possible cell lysis [31]. Cells were separated from medium by cen-
trifugation at 1,250g for 10 minutes at 4˚C and 5 μl of supernatant was used for spent medium
analysis. Metabolites were extracted from the cell pellet by addition of 200 μl of chloroform-
methanol-water (1:3:1) solution and mixed vigorously at 4˚C for 1 hour. The metabolites were
separated from the cell debris by centrifugation at 13,000g for 5 minutes at 4˚C and the sam-
ples were stored under argon gas at -80˚C until analysis. Separation and mass detection of the
metabolites was performed according to [32], using the DionexUltiMate3000 Liquid chroma-
tography system using a SeQuant ZIC-HILIC column coupled to the Orbitrap Exactive mass
spectrometer at Glasgow Polyomics, University of Glasgow. Raw data was processed and ana-
lyzed using the mzMatch [33] and IDEOM [34] software platforms. Metabolite identifications
were given at Level 2 according to the Metabolomics Standards initiative (MSI) where accurate
masses and predicted retention times were used to yield putative annotations but when reten-
tion times of authentic standards were available, the identification should be considered as
Level 1 [35]. Metadata to support the identification of each metabolite is available in the
IDEOM file for each study (S1 Table). It is important to note that many of the metabolite
names given in the IDEOM file are generated automatically as the software provides a best
match to database entries of the given mass and formula. In the absence of additional informa-
tion these must be considered as putatively annotated hits; the confidence score in the column
adjacent to that hit serves as a guide to this. Clearly it is beyond the scope of any study to pro-
vide authenticated annotations to many hundreds of detected compounds, but the full datasets
are included in the spirit of open access data.
Analysis of sterols by GC-MS
Mid log phase cells were taken and washed in PBS before 1.5 ml 25% KOH in 60% ethanol was
added to each 100 mg cells in glass tubes. Samples were incubated at 85˚C for one hour then
an equal volume of n-heptane was added. Samples were vortexed then incubated at room tem-
perature for 10 min. The top layer containing the sterols was transferred to a new glass vial for
analysis.
One microlitre of heptane extract sample was injected into a Split/Splitless (SSL) injector at
270˚C using splitless injection (1 minute) into Trace 1310 gas chromatograph (Thermo Scien-
tific). Helium carrier gas at a flow rate of 1.2 ml/min was used for separation on a TraceGOLD
TG-5SILMS 30 m length with 5 m safeguard × 0.25 mm inner diameter × 0.25 μm film thick-
ness column (Thermo Scientific). The initial oven temperature was held at 50˚C for 2 min.
Separation of sterols was performed using a gradient of 20˚C/min from 50 to 325˚C with an
8.5 minutes final temperature hold at 325˚C. Eluting peaks were transferred through an auxil-
iary transfer temperature of 275˚C into a Q-Exactive GC mass spectrometer (Thermo Scien-
tific). Electron ionisation (EI) was at 70 eV energy, with an emission current of 50 μA and an
ion source of 230˚C. A filament delay of 3.5 minutes was used to prevent excess reagents from
Amphotericin B resistant Leishmania mexicana
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being ionised. Full scan accurate mass EI spectrum at 60,000 resolution were acquired for the
mass range 50 to 750 m/z.
Peak detection used the Xcalibur software (Thermo Scientific). Masses were compared to
those in the NIST/EPA/NIH Mass Spectral Library (EI).
Genomic DNA extraction and sequencing
Cells for genomic DNA extraction were grown to mid-log phase in a 10 ml culture and har-
vested by centrifugation at 1, 250g for 10 minutes and washed once in 1 × PBS. The cells were
re-suspended in 500 μl NTE buffer (10 mM Tris-HCl pH 8.0; 100 mM NaCl; 5 mM EDTA) to
which 25 μl of 10% SDS and 50 μl of 10 mg/ml RNase A (Sigma-Aldrich) were added and
warmed to 37˚C. The solution was mixed by inverting and incubated at 37˚C for 30 minutes.
After addition of 25 μl of 20 mg/ml pronase (Sigma-Aldrich) the lysates were incubated at
37˚C overnight. The samples were then extracted twice with phenol:chloroform:isoamyl alco-
hol (25:24:1) (Sigma-Aldrich) and chloroform, with mixing for 5 minutes between extraction
steps. The aqueous phase was obtained after centrifugation at 16,000g for 10 minutes and the
DNA was precipitated with absolute ethanol and washed once with 70% ethanol. The DNA
was dried in the fume hood and after being dissolved in water the concentration was deter-
mined using a NANODROP 1000 spectrophotometer (Thermo Scientific). Paired-end samples
of the genomic DNA for the progenitor wild-type and derived AmB resistant cells were
sequenced using Illumina GAIIx next generation DNA sequencing platform and analysed at
Glasgow Polyomics, University of Glasgow. All DNA sequence information is deposited at the
European Nucleotide Archive (ENA) under project number PRJEB10872.
Expression of WT CYP51 in AmB resistant cells and GFP-tagging
The expression vector pNUS-HnN for Crithidia fasciculata and Leishmania [36] was used to
express the WT sterol 14α-demethylase gene (LmxM.11.1100) fused to the His-tag at the N-
terminus in AmB resistant L. mexicana. The vector pNUS-GFPcN was used for expression of
both WT and N176I CYP51 with the Green Fluorescent Protein (GFP) tag at the C-terminus
in both resistant and WT L. mexicana. The genes were amplified by PCR using Phusion High-
Fidelity DNA polymerase (New England Biolabs). Primers for pNUS-HnN incorporating NdeI
and XhoI restriction sites (underlined) for WT CYP51 were forward 5’ GCATATGATGATC
GGCGAGCTTCTCC3’ and reverse 5’CTCGAGCTAAGCCGCCGCCTTCT3’. For expression
of the WT and N176I CYP51 in pNUS-GFPcN, the forward and reverse primers were 5’CATA
TGATGATCGGCGAGCTTCTCCT3’ and 5’AGATCTAGCCGCCGCCTTCTTC3’, respecti-
vely, with NdeI and BglII restriction sites. Sterol C14-reductase (LmxM.31.2320) was expressed
in pNUS-GFPcN using forward 5’CATATGATGGCAAAACGCAGAGGTACTG3’ and reve-
rse 5’AGATCTGTATATGTACGGGAACAGCC3’ primers, respectively. The genes were ini-
tially sub-cloned into pGEM-T Easy vector (Promega) and multiplied in XL1 Blue E. coli
competent cells (Promega) prior to cloning into the pNUS vectors. The presence of the gene
fragments was confirmed by their PCR amplification using vector-specific primers designed
from the vector sequences on http://www.ibgc.u-bordeaux2.fr/pNUS/index.html. Thus, pres-
ence of WT CYP51 in the pNUS-HnN was verified with forward 5’CATCATCATCATCAC
AGCAGC3’ and reverse 5’GTCGAAGGAGCTCTTAAAACG3’ primers, while the presence of
both the WT and N176I CYP51 in pNUS-GFPcN was verified with the forward 5’TATCTTC
CACTTGTCAAGCGAAT3’ and reverse 5’CCCATTCACATCGCCATCCAGTTC3’ primers.
Similarly, the presence of these genes was confirmed by PCR in DNA extracted from the trans-
fectants. The presence of mutated chromosomal CYP51 in AmB resistant L. mexicana express-
ing the WT CYP51 gene was confirmed by PCR amplification using a forward primer (5’CG
Amphotericin B resistant Leishmania mexicana
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CGAAATAGATATAAAGCACACG3’) starting from 43 bp upstream of the start codon of
CYP51 or 569 bp from the point mutation and a reverse primer (5’TCGCGAGCGATGATA
ATCTCG3’) starting 213 bp downstream the mutated base resulting in a 788 bp PCR frag-
ment. PCR amplification fragments were sequenced at Eurofins MWG Operon, Germany and
aligned using CLC workbench Genomics software. All primers were purchased from Eurofins
MWG Operon, Germany.
Transfection of L. mexicana and selection for the re-expressors
L. mexicana promastigotes were grown to log phase and 1 × 107 cells were harvested and
washed then re-suspended in 100 μl transfection buffer (90 mM NaPO4 pH7.3; 5 mM KCl;
50 mM HEPES pH7.3; 0.15 mM CaCl2) and added to 10 μg of plasmid DNA in a cuvette before
transfection with an Amaxa biosystems NucleofectorII (Lonza) using program U-033. The
cells were incubated on ice for 10 minutes and then transferred into pre-warmed 10 ml of
Homem supplemented with 10% FBS-Gold and left to recover for 18 hours at 27˚C. G418 dis-
ulfate salt (Sigma-Aldrich) at 50 μg/ml was added to select cells carrying the plasmids. Clones
of the selected cells were obtained in the presence of 50 μg/ml G418 in growth medium by lim-
iting dilution.
Subcellular localisation
Immunofluorescence microscopy was performed with WT and AmB resistant cell lines
expressing GFP-CYP51 or tagged sterol reductase (GFP-SR) from episomal vectors. 200 μl of
mid-log phase cells were collected and washed two times with PBS, fixed in 1% formaldehyde
(methanol-free, Thermo Scientific) for 30 minutes. Triton X-100 (Sigma-Aldrich) was added
up to final concentration 0.1% and incubated for 10 minutes, afterwards, glycine was added to
the final concentration of 0.1 M and incubated for an additional 10 minutes. Cells were centri-
fuged, resuspended in PBS, spread on microscopy slides and left to dry. Slides were washed
with PBS and blocked with PBS, 0.1% Triton X-100, 0.1% BSA (Sigma-Aldrich) for 10 minutes.
Primary antibody against the ER specific chaperone BiP [37], a gift from Professor J. Bangs
(University of Buffalo, New York), was applied in dilution of 1:5000, overnight, at 4˚C. Subse-
quently, slides were washed three times with PBS and incubated with secondary anti-rabbit
Alexa Fluor antibody (Molecular Probes). Following 1 hour incubation, slides were washed
three times with PBS, dried and mounted with 5 μM 4’,6-diamidino-2-phenylindole (DAPI).
Microscopy was performed using Axioscope, Volocity software and processed with ImageJ
software. For mitochondrial staining, cells were incubated with 100 nM MitoTracker red
(Molecular Probes) at 25˚C for 30 minutes. Subsequently, cells were fixed as described above
and mounted with DAPI.
Results
Selection for AmB resistant L. mexicana and its characterisation
AmB resistant L. mexicana promastigotes were selected by stepwise increase in drug concen-
tration in culture medium over 18 passages stretching over six months. During this period, a
23-fold increase (P = 0.0007) in EC50 value above that of the wild-type (WT) was observed (Fig
1 and S1 Fig). Sustained growth in a drug concentration above 0.27 μM could not be achieved.
The acquired AmB resistance was stable over at least 15 passages in drug free medium.
There was no appreciable difference in the growth phenotype between the resistant and the
WT cells, although during the process of resistance induction, the derived AmB resistant cells
Amphotericin B resistant Leishmania mexicana
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required at least five passages of adaptation to a given drug concentration before they would
grow at similar rates to WT.
The cells showing the highest resistance level had a significantly reduced cell body length
compared to the WT cells (P < 0.0001). The late log-phase WT cells and the resistant clone
had average cell body lengths of 11.16 ± 0.19 μm (n = 126) and 9.86 ± 0.16 μm (n = 126),
respectively.
Response of AmB resistant cells to other antileishmanial drugs and
oxidative stress
The AmB resistant cells exhibited mild cross-resistance to potassium antimony tartrate (PAT)
and miltefosine with fold change in EC50 values of 2.9 and 3.9 representing significant differ-
ences (P = 0.0005 and P< 0.0001, respectively) to the WT (Table 1 and S2 Fig). A marginal
1.7-fold increase in the EC50 value (P = 0.0007) to ketoconazole (an inhibitor of sterol synthesis
at the sterol 14α-demethylase step) was also observed in the AmB resistant line.
Fig 1. Selection of AmB resistance in L. mexicana promastigotes. AmB resistance was selected by step-
wise increase in AmB concentrations in the growth medium. The open circles and left y axis indicate the AmB
concentration in the growth medium during the selection over 182 days as shown on x axis. The grey bars and
the right y axis indicate the specific EC50 values (representative single values of three are plotted) for AmB
attained during the selection process at different times as indicated by the x axis.
https://doi.org/10.1371/journal.pntd.0005649.g001
Table 1. Drug sensitivity of AmB resistance cell lines in this and previous studies. While L. mexicana was used here, the quoted values are for L. dono-
vani from Mbongo et al. (1998), and Garcia-Hernandez et al. (2012). Fold change is calculated as the ratio of EC50 value of the resistant cell line to WT for a
given drug. EC50 values are expressed as means of three replicates ± SEM.
Drug WT AmB-R Fold change WT AmB-R Fold change WT AmB-R Fold change
EC50 [μM] EC50 [μM] EC50 [μM]
AmB 0.10 ± 0.004 2.41 ± 0.11 23 0.70 ± 0.01 0.14 ± 0.04 2 0.10 ± 0.01 1.89 ± 0.12 18.9
Pentamidine 4.19 ± 0.27 0.3164 ± 0.008 0.08 - - - 2.7 ± 0.8 1.4 ± 0.2 0.52
Ketoconazole 15.06 ± 0.66 26.05 ± 0.942 1.73 - - - > 1.9 0.13 ± 0.01 < 0.07
Miltefosine 5.82 ± 0.11 22.58 ± 0.20 3.88 5.84 ± 0.43 5.28 ± 0.58 0.90 - - -
SbIII (PAT) 197.6 ± 11.79 564.6 ± 32.65 2.86 87.33 ± 5.72 74.38 ± 4.98 0.85 - - -
Source This study [38] [24]
https://doi.org/10.1371/journal.pntd.0005649.t001
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Interestingly, the AmB resistant cells were found to be more susceptible to pentamidine
(P = 0.0001) with decreases in EC50 values of 13.3-fold.
We also tested the effect of various reagents causing oxidative stress. Exposure of both cell
lines to methylene blue, a stress inducing agent [39], showed that AmB resistant cells were far
more susceptible to this agent with EC50 values of 0.117 ± 0.001 μM against 4.20 ± 0.22 μM for
WT (P< 0.0001).
Addition of 500 μM H2O2 directly to cells induced swelling resulting in their assuming
rounded shapes, and sluggish to no movement. Resistant cells recovered from exposure more
slowly than WT cells (as judged by inspection of flagellar motility) and by 72 hours following
exposure reached average densities of 4 × 106 cell/ml whilst WT cells were at 9 × 106 cells/ml.
Because H2O2 is labile, we also tested the effect of glucose oxidase in medium. Glucose oxi-
dase produces H2O2 continuously [30] and the concentration of enzyme added to medium
can, therefore, act as a surrogate for quantitation of susceptibility to the peroxide. 4.5 mU/ml
of glucose oxidase were required to inhibit growth of WT cells by 50% whilst the EC50 for the
resistant cell line was just 1.8 mU/ml, confirming the increased sensitivity to stress of the resis-
tant cell line.
Untargeted metabolomics reveals significant changes in sterol
metabolism between WT and AmB resistant L. mexicana
Using an untargeted liquid chromatography-mass spectrometry (LC-MS) metabolomics
approach we compared the two cell lines. Principal components analysis (PCA) revealed the
WT and resistant lines to have clear differences (Fig 2A). Among the most significant changes
were alterations around the sterol metabolic pathway. Previous studies in both L. donovani
[19, 24] and L. mexicana [23] have also identified changes to sterols (specifically an increase in
cholesta-5,7,24-trien-3β-ol in L. donovani and 4,14-dimethyl-cholesta-8,24-dienol and other
methyl sterols in L. mexicana). A metabolite of m/z 394.32 putatively identified as ergosta-
Fig 2. LC-MS metabolomics analysis of WT and AmB resistant L. mexicana promastigotes. A. PCA plot of the LC-MS
metabolomic analysis. Each circle represents a single replicate and shaded areas indicate respective 95% confidential intervals;
light blue, WT cells; green, AmB resistant cells; red, fresh medium; magenta, WT spent medium; dark blue, AmB resistant cells
spent medium. B. Representative sterols as detected by LC-MS metabolomic analysis significantly changing between WT and
AmB resistant cells. Mass of these metabolites is listed since specific identification is not possible by LC-MS, but formulae of
410.3547 = C29H46O; 426.3497 = C29H46O2; 394.3235 = C28H420. Mean values of three replicates are plotted, error bars represent
standard deviations.
https://doi.org/10.1371/journal.pntd.0005649.g002
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5,7,22,24(28)-tetraen-3β-ol was diminished in resistant cells compared to WT cells (Fig 2B and
S1 Table) while a metabolite of m/z 410.35 putatively identified as 4,4-dimethylcholesta-
8,14,24-trien-3β-ol and another with m/z 426.35 consistent with 4α-formyl-4β-methylcho-
lesta-8-24-dien-3β-ol were more abundant in resistant cells compared to WT cells (Fig 2B and
S1 Table).
While the LC-MS approach taken allows comprehensive coverage of the metabolome and is
thus ideally suited to initial identification of those areas of metabolism changing in response to
biological perturbation, the hydrophilic interaction liquid chromatography (HILIC)-based liq-
uid chromatography platform is not suitable for separation and robust identification of indi-
vidual lipids. Having identified that changes in sterol metabolism were key, we adopted a gas
chromatography (GC)-MS approach since this methodology had been previously applied to
the identification of sterol metabolism in L. mexicana [40].
Fig 3 shows chromatograms obtained from the GC-MS, and identities of the detected peaks
are indicated in Table 2 based on matches with the NIST library (https://www.nist.gov/srd/
nist-standard-reference-database-1a-v14). The major difference between WT and AmB resis-
tant cells is depletion of peak 6 representing ergosterol (the most abundant sterol in WT) and
concomitant increase in peak 5, corresponding with 14-methylergosta-8,24(28)-dien-3β-ol in
the resistant cell line. Peak 4, not detected in WT, is abundant in resistant cells, and corre-
sponds to 4,4-dimethylcholesta-8,14,24-trien-3β-ol, a product of the sterol 14α-demethylase
reaction (note, however, that isomers of this compound exist that we cannot distinguish). In
addition, peaks 3 and 8 are increased 50-fold and 80-fold, respectively, in the AmB resistant
cell line, putatively identified as ergosta-5,24(28)-dien-3β-ol and 4,14-dimethylergosta-8,24
(28)-dien-3β-ol. The level of cholesterol was unchanged because it is acquired from the
medium rather than synthesised [41].
Fig 3. Total ion chromatograms for a) AmB resistant (R) and b) wild type (WT). Extracted sterols were
analysed by high resolution accurate mass Q-Exactive GC Orbitrap. Nine unique sterols were identified in the
retention time region from 17 to 18.4 min. The identification of these sterols is listed in Table 2. Asterisks
denote polysiloxane contaminant peaks that co-elute with sterol peaks. Three replicates of each extraction
show high reproducibility with regard to peak height.
https://doi.org/10.1371/journal.pntd.0005649.g003
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The detected sterols were mapped onto a pathway based on work by Roberts et al., [42] and
metacyc.org database (Fig 4). Overall, components from the upper part of the pathway are
accumulated whereas intermediates of the downstream steps are decreased.
Replacement of ergostane-type sterols in WT cells with cholestane-type sterols in resistant
derivatives, are similar to those noted in L. donovani promastigotes selected for resistance [24]
and also a field isolate of L. donovani from a refractory patient [19]. In a separate study, L. mex-
icana selected for resistance had also lost ergosterol, but in this case the sterol species that accu-
mulated was 4,14-dimethylcholesta-8,24-dienol [23], indicating that there may be several
distinct ways whereby loss of ergosterol synthesis can be achieved, with the accompanying
accumulation of other sterols. In principle, the loss of any enzyme in the ergosterol synthetic
pathway could lead to loss of production of that sterol and acquisition of resistance to AmB.
For example, Pourshafie et al. [26] point to possible mutations in C-24-Δ-sterol-methyltrans-
ferase causing the increase in cholesta-5,7,24-trien-3β-ol they identified.
The related parasite Trypanosoma brucei accumulates exogenous cholesterol for membrane
biogenesis [43] and L. donovani deficient in a cytochrome P450 enzyme related to sterol 14α-
demethylase, termed CYP5122A1, produce less ergosterol than WT cells and grow less well
but recover WT growth rates if medium is supplemented with exogenous ergosterol [44]. We
therefore tested whether addition of exogenous ergosterol would accumulate in membranes of
our resistant cells and re-sensitise them to AmB. However, addition of exogenous ergosterol
(7.6 μM, as used in reference [44]) for 5 passages prior to testing drug efficacy, failed to re-sen-
sitise, rather it further reduced sensitivity (2.84-fold increase in EC50 value for AmB
(P = 0.0004)) which could be attributed to the drug binding ergosterol in medium.
Genomic DNA sequencing and comparison of WT and AmB resistant L.
mexicana reveals a single nucleotide polymorphism in sterol 14α-
demethylase
Whole genome sequencing of the resistant line and its WT progenitor (passaged in parallel
during the course of resistance selection) resulted in more than 50% of the reads being aligned
in both cases to the reference L. mexicana MHOM/GT/2001/U1103 genome (17,138,430 and
15,392,124 reads out of totals of 32,238,036 and 27,514,220 reads which were obtained for the
Table 2. Identification of the sterol peaks indicated in Fig 3. Identification is based on matches with the NIST library after fragmentation and the scores
are indicated. Abundance relative to the total sterol content is indicated in each cell line, and the fold change of that.
Label Base Fragment Ion
(m/z)
Molecular Ion
(m/z)
Fragment
Formula
NIST Library Match NIST
SCORE
WT
% of
Total
Resistant
% of Total
Fold
Change
1 301.28903 386.35440 C21H33O Cholesterol 765 0.10 0.11 1.1
2 369.31524 384.3384 C26H41O 5α-Cholesta-8,24-dien-3β-
ol = zymosterol
656 0.24 0.02 0.083
3 383.33083 398.35436 C27H43O Ergosta-5,24(28)-dien-3β-ol 616 0.02 1.02 51
4 377.32047 410.35460 C28H41 0.00 6.72 -
5 397.34652 412.37016 C28H45O 14α-Methyl-5α-ergosta-8,24(28)-
dien-3β-ol
708 0.12 72.46 604
6 363.30477 396.33876 C27H39 Ergosterol 713 86.32 12.83 0.15
7 271.20583 398.35586 C19H27O 9.80 4.02 0.41
8 411.36225 426.38595 C29H47O 4α,14α-Dimethyl-5α-ergosta-8,24
(28)-dien-3β-ol
694 0.02 1.63 81.5
9 411.36240 426.38596 C29H47O Lanosterol 599 0.09 0.15 1.67
10 377.32030 410.35440 C28H41 (3β)-Stigmasta-5,7,22-trien-3-ol 727 3.28 1.05 0.32
https://doi.org/10.1371/journal.pntd.0005649.t002
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Fig 4. Ergosterol biosynthetic pathway with indicated sterols detected in metabolomic analyses. The pathway is based on the metacyc.org
database and Roberts et al. [42], however, the exact topology of the pathway in Leishmania is unknown. Colour arrows and numbers indicate sterols
Amphotericin B resistant Leishmania mexicana
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WT and the AmB resistant clone, respectively, were aligned). Comparison of read coverage
depth between AmB resistant and WT cells showed variations in chromosome copy numbers.
An extra copy was observed to have been gained for chromosomes 05, 19, 22, and 27 and there
was loss of a copy for chromosomes 12 and 17 of the AmB resistant cells as compared to the
parental WT cells. In addition, a total of 5,047 single nucleotide polymorphisms (SNP) distin-
guish the WT and resistant lines.
Since the metabolomic data indicated changes in sterol metabolism we looked specifically
for any genetic alterations in genes encoding enzymes of this pathway in AmB resistant cells.
A single homozygous SNP was found among genes encoding the enzymes of the ergosterol
pathway, namely in sterol 14α-demethylase (EC 1.14.13.70), where a non-synonymous muta-
tion from A to T results in an amino acid alteration from asparagine to isoleucine (N176I) in
this enzyme. Lines of several Candida species resistant to AmB also had mutations to sterol
14α-demethylase (ERG11) [45–47] which lead to a cessation of ergosterol production. These
cells, however, were also resistant to azoles that target the demethylase whilst our Leishmania
cell line was not. Since the Candida lines also accumulate lanosterol (the substrate of sterol
14α-demethylase) whilst our Leishmania cell line accumulated the enzyme’s product, we con-
clude that the Candida mutants have lost enzyme activity whilst our mutant retains demethy-
lase activity but fails to provide the product into later steps of the ergosterol synthetic pathway.
Interestingly, 4,4-dimethylcholesta-8,14,24-trien-3β-ol is the product of the sterol 14α-
demethylase reaction and it was increased in the resistant cells, indicating that the enzyme
itself was functional, but that its metabolic product accumulates and no longer feeds the
remainder of the ergosterol pathway. Modelling of the site of the mutation revealed it to reside
on an external loop of the enzyme, some way from the active site (Fig 5A). This is compatible
with the enzyme’s retaining activity, but somehow becoming divorced from other features
required to progress the product further through the ergosterol pathway. In L. donovani, gene
knockout experiments with sterol 14α-demethylase concluded that the enzyme was essential
and double knockout only possible in the presence of an expressed episomal version of the
gene [48]. By contrast, null mutants were made in L. major and the cells were viable, albeit
hyper sensitive to temperature stress [49].
An alignment of the primary sequences of sterol 14α-demethylase from different trypanoso-
matids, yeast and humans (Fig 5B) revealed that the mutated asparagine residue is conserved
among trypanosomatid species analysed and not in yeast (Saccharomyces cerevisiae) or humans
(Homo sapiens). The conservation could indicate important function across the Kinetoplastidae,
beyond enzyme activity, for instance it could be important for protein-protein interactions.
Expression of WT L. mexicana sterol 14α-demethylase in AmB resistant
L. mexicana restores ergosterol synthesis and AmB sensitivity
Connection of ergosterol synthesis with AmB resistance was reported in previous studies, and
here we observed substantial changes in the ergosterol biosynthetic pathway including loss of
ergosterol, and mutation in sterol 14α-demethylase (CYP51). We therefore re-expressed the
WT allele in resistant cells to see if ergosterol synthesis could be restored and whether rever-
sion to AmB sensitivity occurred. Indeed, LC-MS revealed the restoration of the key marker of
ergosterol synthesis (Fig 6), and concomitant reversion to AmB sensitivity was also associated
with expression of WT CYP51 in resistant cells.
significantly changed in AmB resistant cells when compared to WT, and their relative abundance. Asterisks mark metabolites detected by LC-MS only, thus
their identification is only putative.
https://doi.org/10.1371/journal.pntd.0005649.g004
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The line now expressing WT CYP51 was found to be less sensitive to ketoconazole with a
fold change in EC50 value of 2.6 (P = 0.0072) as compared to WT cells indicating a possible
over-expression of the demethylase, a known target of ketoconazole, in the re-expressor line
(Table 3). The implication of overexpression would be the presence of more protein, requiring
more drug to achieve the same level of inhibition of demethylase activity. The AmB resistant
Fig 5. Structural and sequence context of the N176I mutation in sterol 14α-demethylase. A) A model of
sterol 14α-demethylase from wild type L. mexicana. The model was built in Modeller (CCP4 Program Suite
6.3.0) based on the structure of CYP51 from L. infantum, PDB ID 3L4D, 97% amino acid sequence identity.
Distal P450 view. The heme is shown as a stick model, the carbon atoms are grey, the active site area is
circled. The protein ribbon is rainbow coloured from blue (N-terminus) to red (C-terminus). N176 is shown as a
stick model and marked, the carbon atoms are cyan. B) Primary structure alignment of sterol 14α-
demethylase of trypanosomatids, yeast, and human. The N176 residue, conserved in Leishmania and
trypanosome species, but not in yeast and human, is indicated.
https://doi.org/10.1371/journal.pntd.0005649.g005
Fig 6. Reversal in AmB sensitivity and sterol composition after WT CYP51 re-expression in the AmB
resistant cell line. Red bars represent EC50 values in WT, AmB resistant cells, and AmB resistant cells re-
expressing WT CYP51. Mean values of three replicates are shown, error bars represent standard deviations,
p < 0.0001. Blue bars represent intensity detected for a sterol C28H48O, consistent with ergosta-5,7,22E-trien-
3β-ol.
https://doi.org/10.1371/journal.pntd.0005649.g006
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cells expressing the WT gene for sterol 14α-demethylase were found to have lost hypersensitiv-
ity to pentamidine by reverting back to the WT EC50 value for this drug and sensitivity to mil-
tefosine was also restored.
Subcellular localisation of sterol 14α-demethylase and sterol
C14-reductase in WT and resistant lines
Since the mutation that affects sterol 14α-demethylase falls outside the active site and the
enzyme retains activity as assessed by the ability of cells to convert lanosterol to its product, the
mutation in the enzyme must prevent entry of the product into the remainder of the sterol
pathway. Altering the subcellular localisation of the enzyme such that the product is divorced
from the next enzyme in the pathway would offer a means to allow this. We therefore tested
the subcellular localisation of both WT and mutant enzyme by tagging both with green fluo-
rescent protein (GFP) at the C-terminus, the N-terminus having been proposed as important
to localisation [44, 50]. A staining of the GFP-tagged CYP51 expressing cells with antibodies to
the endoplasmic reticulum (ER) specific protein BiP, revealed localisation to the ER. There
was no indication that the mutated enzyme localises differently from the WT enzyme at this
resolution (Fig 7) hence the mutation did not seem to affect the broad compartmental localisa-
tion of the enzyme. We also tested localisation of the next enzyme in the sterol pathway, sterol
C14-reductase, by tagging with GFP and it too was found in the endoplasmic reticulum in
both WT and AmB resistant cells (Fig 7). The point mutation in CYP51 therefore has no effect
on organellar targeting of that protein, nor the next enzyme in the pathway, although we have
not been able to ascertain whether these enzymes are linked in either cell line. Higher resolu-
tion microscopy or the use of different tagging system might yield more information on the
localisation of the enzymes.
Discussion
The leishmaniases represent a significant health burden in many parts of the tropical and sub-
tropical world. Elimination is a public health priority. Treatment of diagnosed patients is cen-
tral to elimination plans. AmB has, in recent years, gained favour as a first line treatment for
the leishmaniases, particularly in its liposomal formulation, AmBisome, which can be given in
lower doses and is substantially less toxic than non-liposomal formulations of the drug. Effi-
cacy is such that a single injection of AmBisome (10 mg/kg) is currently proposed for primary
intervention [11]. A single dose regimen carries the public health benefit of assured compli-
ance with no need for prolonged hospitalisation. However, the policy also brings with it a risk
of resistance selection. Future plans for sustained therapeutic intervention with combination
therapies [9, 10, 51, 52] once the best combination regimens have been chosen, might mitigate
against this risk. However, where AmB is part of the combination, selection of resistance dur-
ing the single shot monotherapy phase of the control programme would be calamitous.
Table 3. Effect of anti-leishmanial drugs on AmB resistant cells expressing the WT CYP51. Mean values of three replicates are shown with SEM
values.
Drug EC50 [μM] Fold change AmB-R/WT EC50 [μM] Fold change
re-expressor/WTWT AmB-R Re-expresser
Pentamidine 4.19 ± 0.27 0.32 ± 0.01 0.08 4.18 ± 0.10 0.997
Miltefosine 5.82 ± 0.11 22.58 ± 0.20 3.88 3.591 ± 0.06 0.62
Ketoconazole 15.46 ± 0.84 24.73 ± 0.57 1.60 40.23 ± 4.82 2.60
https://doi.org/10.1371/journal.pntd.0005649.t003
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The fact that resistance to AmB has not emerged to any great extent in the treatment of fun-
gal infections, in spite of over 50 years of use [14, 15], coupled to various laboratory based
experiments corroborating the difficulty of selecting stable AmB resistance [15] has led to the
perception that the benefits of the single dose AmBisome approach outweigh the risks of
resistance.
Several laboratory studies, however, have revealed that Leishmania can be selected for resis-
tance to AmB, both as promastigotes and also amastigotes [23, 24]. Moreover, the first reports
of parasites that are of reduced sensitivity to the drug being isolated from patients refractory to
AmB are emerging [19, 20], in spite of the drug’s use against the leishmaniases having been rel-
atively limited. Genes responsible for resistance have yet to be identified, although a number of
common features have been detected in AmB resistant Leishmania cell lines. These include
changes in sterol metabolism, where ergosterol, the primary sterol of WT Leishmania cell
membranes is reduced or lost and replaced by different cholestane-type sterols. Enhanced abil-
ity to resist oxidative stress is also a prominent feature and proteomic analysis [19, 23, 24] has
demonstrated increases in abundance of stress related proteins.
Here we set out to seek genes responsible for resistance by applying a polyomics-based
approach, combining data from untargeted metabolomics analysis with whole genome
Fig 7. Immunofluorescence microscopy of CYP51 and sterol reductase (SR) in WT and AmBR cells. A) WT and the mutated N176I version of
CYP51 were tagged with a GFP (green). α-BiP antibody was used as a marker for the endoplasmic reticulum (red; (37)). Clear overlap with the marker was
detected in all cell lines tested. First line, WT expressing WT CYP51; second line, WT cells expressing N176I CYP51 (conferring resistance to AmB). SR
was tagged with GFP and this construct was transfected into both WT and AmBR cells (third line, WT SR in WT cells; fourth line, WT SR in AmBR cells).
Again, SR localised to the endoplasmic reticulum in both WT and AmBR cells, without any obvious difference. B) All the cell lines were probed with
MitoTracker in order to test possible mitochondrial localisation. None of the tagged proteins colocalised with MitoTracker.
https://doi.org/10.1371/journal.pntd.0005649.g007
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sequencing. We focused on L. mexicana promastigotes which are relatively easy to work with
to generate an understanding of how resistance to AmB can occur. Ultimately it will be neces-
sary to test the relevance of these results to L. donovani amastigote forms that are responsible
for visceral leishmaniasis, the primary target for AmB therapy.
We identified changes in sterol metabolism with a loss of ergosterol and could associate this
with a single change to the enzyme sterol 14α-demethylase. PCR analysis of the gene encoding
this enzyme from parasites selected after 50 days of drug exposure with low level resistance
(Fig 1) had a WT sterol 14α-demethylase gene. By day 162, after higher level resistance had
been selected, the mutant allele had appeared, indicating that lower level resistance was associ-
ated with changes other than the alteration is sterol metabolism, but the acquisition of higher
level resistance required loss of ergosterol. Sterol 14α-demethylase (CYP51) has been consid-
ered an important target for chemotherapy as the azole drugs like ketoconazole and itracona-
zole inhibit this enzyme and show anti-leishmanial activity, albeit with disappointing results in
vivo. Although gene knockout experiments indicated the gene was essential in L. donovani
[48], recently it was shown that a L. major null mutant of sterol 14α-demethylase was viable
[49]. These cells accumulated the 14-methyl sterols, 14-methyl fecosterol and 14-methyl
zymosterol, and also acquired resistance to AmB, due to loss of ergosterol production. They
also acquired resistance to azoles exemplified by itraconazole, which targets the demethylase.
Our resistant line retained sensitivity to ketoconazole, which is explained by its having retained
the demethylase activity, which also explains why the resistant line accumulates the enzyme’s
product 4,4-dimethylcholesta-8,14,24-trien-3β-ol.
In yeast, the enzymes of ergosterol biosynthesis have been proposed to exist within a multi-
enzyme complex, the ergosome [53]. By analogy, a similar multi-enzymatic complex could
exist in Leishmania, although no evidence for such a complex has yet been described. To test
whether the mutation we identified in sterol 14α-demethylase led to mislocalisation of the
enzyme, we tagged both WT and mutant copies with GFP and followed cellular localisation. In
L. mexicana the enzyme is found primarily in the ER as in L. major [49].This localisation is
retained in both WT and resistant lines. No gross change in localisation of the following
enzyme, sterol C14-reductase, is apparent when mutated CYP51 N176I is expressed. It seems
likely, therefore, that the mutation, instead, prevents an interaction with this or another pro-
tein and this alteration may prevent the channelling of the product into the subsequent reac-
tions of ergosterol synthesis leading to accumulation of 4,4-dimethylcholesta-8,14,24-trien-3β-
ol and other intermediates. The accumulated sterols are presumably sufficient for key roles of
sterols in the resistant cell lines. Leishmania therefore may contain a multi-enzyme ergosome
analogous to that described in yeast [53] and direct protein interactions may be essential for
the proper function. We plan to investigate the presence and composition of the leishmanial
ergosome in future work
It was also of note that the AmB resistant line we selected was hypersensitive to oxidative
stress (created by hydrogen peroxide and methylene blue) and to pentamidine, an anti-leish-
manial drug previously indicated to exert its mode of action through induction of oxidative
stress [54, 55]. Hypersensitivity to hydrogen peroxide, methylene blue and pentamidine was
reversed along with the AmB resistance phenotype upon expression of the WT demethylase
gene. Possible explanations for this increase in sensitivity to oxidative stress include changes to
the cell membrane integrity and fluidity after loss of ergosterol, as was observed previously [19,
24], or possibly the enhanced capability of ergosterol itself as an agent of protection against
oxidative stress [56]. Increases in stress-response proteins have also been reported in other
AmB resistant lines [22, 25]. It is possible that this relates to their selection leading to loss of
ergosterol and the concomitant increase in sensitivity to oxidative stress is secondarily com-
pensated by additional changes to enzyme pathways dealing with oxidative stress. It is
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important to note here that other leishmanicides may lead to selection of enhanced resistance
to oxidative stress [57], hence these stress tolerant parasites might form resistance to AmB rela-
tively readily. Even environmental pressures, such as high levels of arsenic in drinking water,
can lead to selection of antimony resistance and reduced oxidative stress sensitivity [58]. The
potential of Leishmania strains, pre-adapted in ways that will allow relatively easy selection for
AmB resistance is therefore of significant concern.
Resistance to AmB in this study therefore relates to changes in the sterol composition of the
parasite’s membrane with AmB binding ergostane-type sterols replaced by less avidly binding
cholestane-type sterols. This is achieved, in this instance, by mutating an enzyme, sterol 14α-
demethylase, of the sterol synthesis pathway in a manner which affects not its active site but its
ability to channel its enzymatic product to subsequent steps of the pathway. A survey of the lit-
erature describing other AmB resistant Leishmania indicates that loss of ergostane sterols is a
common step in development of resistance to the drug [19, 23, 24]. However, it appears likely
that different mutations to various enzymes in the pathway can contribute. The fact that treat-
ment failures with AmB are reported in India and in at least one case sterol metabolism is
changed [19] points to a necessity to contemplate spread of resistance to this drug. The fre-
quency with which changes to sterol composition emerge does point to possible tests to survey
for resistance. In addition to seeking different genes whose mutation can cause resistance, sim-
ple tests for sterol composition including spectrophotometric discrimination between ergosterol
and cholestane-type sterols [59, 60] offer approaches with which to develop tests for resistance
to the drug. Mutations in sterol 14α-demethylase can also be identified, but other mutations too
might also provide the same ultimate result of loss of ergosterol synthesis and further analysis of
genes associated with resistance lines will enhance understanding in this area.
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